Skip to main content
ALGORAE PHARMACEUTICALS LIMITED logo

ALGORAE PHARMACEUTICALS LIMITED — Investor Relations & Filings

Ticker · 1AI ISIN · AU0000296022 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,159 across all filing types
Latest filing 2020-04-16 Capital/Financing Update
Country AU Australia
Listing ASX 1AI

About ALGORAE PHARMACEUTICALS LIMITED

https://algoraepharma.com/

Algorae Pharmaceuticals Limited is a biopharmaceutical company focused on the discovery and development of novel therapeutic solutions for complex medical conditions. The company leverages its proprietary artificial intelligence platform, AlgoraeOS, to streamline the drug discovery process and identify synergistic drug combinations. Its research pipeline primarily targets neurodegenerative diseases and other areas of high unmet clinical need. Key development programs include AI-116, a combination therapy aimed at treating dementia and Alzheimer's disease. By integrating advanced computational modeling with traditional pharmacological research, the company seeks to accelerate the transition of candidates from preclinical stages to clinical trials, optimizing therapeutic efficacy and safety profiles.

Recent filings

Filing Released Lang Actions
LCT Covid-19 Business Impact Update 2 pages 437.4KB
Capital/Financing Update Classification · 95% confidence The document is an ASX announcement from Living Cell Technologies Limited providing an update on the business impact of Covid-19, including project delays, cost-cutting measures, and cash management. It does not contain financial statements, detailed financial analysis, or regulatory filings such as annual or interim reports. It is a corporate update on operational and financial impacts due to external events, typical of a Capital/Financing Update. The document is about ongoing cash management and financial prudence rather than a formal earnings release or annual report. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2020-04-16 English
Half Yearly Report and Accounts 22 pages 1.3MB
Interim / Quarterly Report Classification · 100% confidence The document is titled as a 'Half yearly report ended 31 December 2019' and includes detailed financial data such as consolidated loss after tax, net assets, cash flows, and directors' report for the half year period. It also contains financial statements and an independent auditor's review report. The presence of comprehensive financial statements and management discussion for a six-month period indicates this is an Interim / Quarterly Report. The document is about 15,000 characters long, which is substantial and contains actual financial data, not just an announcement or summary. Therefore, it fits the definition of an Interim / Quarterly Report (IR). H1 2020
2020-02-26 English
Appendix 4C - quarterly 7 pages 332.9KB
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Appendix 4C Quarterly Cash Flow Report 31 December 2019' and is described as a quarterly cash flow report for the quarter ended 31 December 2019. It contains detailed financial data including consolidated statements of cash flows from operating, investing, and financing activities, as well as reconciliation of cash and cash equivalents. The document references compliance with Listing Rule 4.7B and Australian Accounting Standards. The length of the document (13,594 characters) and the presence of substantive financial data confirm it is a full quarterly financial report rather than a brief announcement or certification. Therefore, this document fits the definition of an Interim / Quarterly Report (IR). Q2 2019
2020-01-29 English
Resignation of Joint Company Secretary 2 pages 434.7KB
Board/Management Information Classification · 100% confidence The document is an ASX announcement regarding the resignation of a Joint Company Secretary. It is a short announcement (4284 characters) and does not contain financial data, management discussion, or detailed report content. It is clearly about a change in senior management personnel, specifically the resignation of a company secretary. This fits the category of Board/Management Information (MANG).
2019-12-19 English
Response to Appendix 3Y Query 3 pages 246.9KB
Director's Dealing Classification · 95% confidence The document is a letter from Living Cell Technologies Limited responding to a query from the Australian Securities Exchange (ASX) regarding a late filing of Appendix 3Y, which is a Change of Director's Interest Notice. The content focuses on compliance with ASX Listing Rules 3.19A and 3.19B concerning timely disclosure of directors' interests. It discusses the administrative oversight causing the late filing and the company's arrangements to ensure future compliance. There are no financial statements, earnings data, or detailed financial analysis present. The document is a regulatory compliance communication related to director shareholding disclosures, which fits the category of Director's Dealing filings. Therefore, the appropriate classification is DIRS (Director's Dealing). The document length (6637 characters) and content confirm it is not a brief announcement or a report publication notice but a substantive response letter about director share transactions.
2019-12-08 English
Appendix 3B 8 pages 392.9KB
Capital/Financing Update Classification · 100% confidence The document is titled 'Appendix 3B New issue announcement' and contains detailed information about the issuance of new securities, including the class of securities, number issued, exercise prices, vesting and expiry dates, and other terms. It also includes sections on quotation of securities and agreements related to the listing on the ASX (Australian Securities Exchange). The document references ASX rules and compliance requirements for new securities issuance. This type of document is a formal announcement related to capital raising activities, specifically the issuance of new shares or options. It is not a full financial report, earnings release, or management discussion, but rather a regulatory announcement about new securities issuance and quotation application. Therefore, the appropriate classification is 'Capital/Financing Update' (CAP). The document length and detail confirm it is not a brief announcement or a report publication notice, but a substantive filing about capital changes.
2019-12-05 English

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.